Neuronetics, Inc.STIM
Key ratios
FCF / Sales
-7.3%TTM
2025
-14.2%2024
-43.3%2023
-48.2%
Net margin
-19.6%TTM
2025
-26.2%2024
-58.4%2023
-42.3%
ROA
-13.7%2025
2024
-16.5%2023
-15.4%
ROE
-116.1%TTM
2025
-134.9%2024
-132.5%2023
-66.2%
Revenue growth
39.6%TTM
2025
99.2%2024
5.0%2023
9.4%
Recent news
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Track STIM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer